BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 11303586)

  • 1. The association between polymorphisms in the CYP17 and 5alpha-reductase (SRD5A2) genes and serum androgen concentrations in men.
    Allen NE; Forrest MS; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2001 Mar; 10(3):185-9. PubMed ID: 11303586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum sex steroid hormone levels and polymorphisms of CYP17 and SRD5A2: implication for prostate cancer risk.
    Kakinuma H; Tsuchiya N; Habuchi T; Ohyama C; Matsuura S; Wang L; Nakamura A; Kato T
    Prostate Cancer Prostatic Dis; 2004; 7(4):333-7. PubMed ID: 15477877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between two polymorphisms in the SRD5A2 gene and serum androgen concentrations in British men.
    Allen NE; Reichardt JK; Nguyen H; Key TJ
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):578-81. PubMed ID: 12815006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5alpha-reductase type II (SRD5A2) genes on prostate-cancer risk among the Japanese population.
    Yamada Y; Watanabe M; Murata M; Yamanaka M; Kubota Y; Ito H; Katoh T; Kawamura J; Yatani R; Shiraishi T
    Int J Cancer; 2001 Jun; 92(5):683-6. PubMed ID: 11340572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study.
    Hsing AW; Chen C; Chokkalingam AP; Gao YT; Dightman DA; Nguyen HT; Deng J; Cheng J; Sesterhenn IA; Mostofi FK; Stanczyk FZ; Reichardt JK
    Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1077-82. PubMed ID: 11588134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2).
    Lunn RM; Bell DA; Mohler JL; Taylor JA
    Carcinogenesis; 1999 Sep; 20(9):1727-31. PubMed ID: 10469617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer.
    Lévesque É; Laverdière I; Lacombe L; Caron P; Rouleau M; Turcotte V; Têtu B; Fradet Y; Guillemette C
    Clin Cancer Res; 2014 Feb; 20(3):576-84. PubMed ID: 24277450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population.
    Onen IH; Ekmekci A; Eroglu M; Polat F; Biri H
    DNA Cell Biol; 2007 Feb; 26(2):100-7. PubMed ID: 17328668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5alpha-Reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia.
    Hayes VM; Severi G; Padilla EJ; Morris HA; Tilley WD; Southey MC; English DR; Sutherland RL; Hopper JL; Boyle P; Giles GG
    Int J Cancer; 2007 Feb; 120(4):776-80. PubMed ID: 17136762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men.
    Yu MW; Yang YC; Yang SY; Cheng SW; Liaw YF; Lin SM; Chen CJ
    J Natl Cancer Inst; 2001 Nov; 93(21):1644-51. PubMed ID: 11698569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between a polymorphism in CYP17 with plasma hormone levels and prostate cancer.
    Haiman CA; Stampfer MJ; Giovannucci E; Ma J; Decalo NE; Kantoff PW; Hunter DJ
    Cancer Epidemiol Biomarkers Prev; 2001 Jul; 10(7):743-8. PubMed ID: 11440959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of prostate cancer risk and aggressiveness to androgen pathway genes: SRD5A2, CYP17, and the AR.
    Cicek MS; Conti DV; Curran A; Neville PJ; Paris PL; Casey G; Witte JS
    Prostate; 2004 Apr; 59(1):69-76. PubMed ID: 14991867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways.
    Latil AG; Azzouzi R; Cancel GS; Guillaume EC; Cochan-Priollet B; Berthon PL; Cussenot O
    Cancer; 2001 Sep; 92(5):1130-7. PubMed ID: 11571725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypospadias risk and polymorphism in SRD5A2 and CYP17 genes: case-control study among Indian children.
    Samtani R; Bajpai M; Vashisht K; Ghosh PK; Saraswathy KN
    J Urol; 2011 Jun; 185(6):2334-9. PubMed ID: 21511288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population.
    Sobti RC; Onsory K; Al-Badran AI; Kaur P; Watanabe M; Krishan A; Mohan H
    DNA Cell Biol; 2006 May; 25(5):287-94. PubMed ID: 16716118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of the SRD5A2 gene and the risk of prostate cancer.
    Dušenka R; Tomaškin R; Kliment J; Dobrota D; Dušenková S; Vilčková M; Sivoňová MK
    Mol Med Rep; 2014 Dec; 10(6):3151-6. PubMed ID: 25310105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C-infected patients.
    Rossi L; Leveri M; Gritti C; De Silvestri A; Zavaglia C; Sonzogni L; Silvestri L; Civardi E; Mondelli MU; Silini EM
    J Hepatol; 2003 Oct; 39(4):564-70. PubMed ID: 12971967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. V89L polymorphism of the 5alpha-reductase Type II gene (SRD5A2), endogenous sex hormones, and prostate cancer risk.
    Boger-Megiddo I; Weiss NS; Barnett MJ; Goodman GE; Chen C
    Cancer Epidemiol Biomarkers Prev; 2008 Feb; 17(2):286-91. PubMed ID: 18268111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Analysis of the SRD5A1 and SRD5A2 Genes in Patients with Benign Prostatic Hyperplasia with Regard to Metabolic Parameters and Selected Hormone Levels.
    Rył A; Rotter I; Grzywacz A; Małecka I; Skonieczna-Żydecka K; Grzesiak K; Słojewski M; Szylińska A; Sipak-Szmigiel O; Piasecka M; Walczakiewicz K; Laszczyńska M
    Int J Environ Res Public Health; 2017 Oct; 14(11):. PubMed ID: 29084161
    [No Abstract]   [Full Text] [Related]  

  • 20. Polymorphic markers in the 5alpha-reductase type II gene and the incidence of prostate cancer.
    Lamharzi N; Johnson MM; Goodman G; Etzioni R; Weiss NS; Dightman DA; Barnett M; DiTommaso D; Chen C
    Int J Cancer; 2003 Jul; 105(4):480-3. PubMed ID: 12712437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.